Mohini Ranganathan1,2,3, Joao P De Aquino4,5,6, Jose A Cortes-Briones4,5,6, Rajiv Radhakrishnan4,5,6, Brian Pittman4, Savita Bhakta7, Deepak C D'Souza4,5,6. 1. Department of Psychiatry, Yale University School of Medicine, 300 George St, Suite 901, New Haven, CT, 06510, USA. mohini.ranganathan@yale.edu. 2. U.S. Department of Veterans Affairs, Clinical Neurosciences Division, VA Connecticut Healthcare System, 116A, 950 Campbell Avenue, West Haven, CT, 06511, USA. mohini.ranganathan@yale.edu. 3. Clinical Neuroscience Research Unit, Connecticut Mental Health Center, 34 Park St, New Haven, CT, 06519, USA. mohini.ranganathan@yale.edu. 4. Department of Psychiatry, Yale University School of Medicine, 300 George St, Suite 901, New Haven, CT, 06510, USA. 5. U.S. Department of Veterans Affairs, Clinical Neurosciences Division, VA Connecticut Healthcare System, 116A, 950 Campbell Avenue, West Haven, CT, 06511, USA. 6. Clinical Neuroscience Research Unit, Connecticut Mental Health Center, 34 Park St, New Haven, CT, 06519, USA. 7. Department of Psychiatry, University of California San Diego School of Medicine, San Diego, 9500 Gilman Dr, La Jolla, CA, 92094, USA.
Abstract
RATIONALE: The catechol-O-methyl transferase (COMT) enzyme has been implicated in determining dopaminergic tone and the effects of delta-9-tetrahydrocannabinol (THC) in the human brain. OBJECTIVE: This study was designed to evaluate the effect of (1) a functional polymorphism and (2) acute pharmacological inhibition of COMT on the acute response to THC in humans. METHODS: Sub-study I: The effect of intravenous (IV) THC (0.05 mg/kg) was investigated in 74 healthy subjects genotyped for the COMT rs4680 (Val/Met) polymorphism in a 2-test-day double-blind, randomized, placebo-controlled study. Sub-study II: COMT rs4680 homozygous subjects (Val/Val and Met/Met) from sub-study I received the COMT enzyme inhibitor tolcapone (200 mg) followed by IV THC or placebo on two additional test days. Subjective, behavioral, and cognitive data were obtained periodically on each test day. RESULTS: Sub-study I: Val/Val individuals were most sensitive to THC-induced attention and working memory deficits. In contrast, the psychotomimetic and subjective effects of THC were not influenced by COMT genotype. Sub-study II: Tolcapone reduced THC-induced working memory deficits, but not THC's psychotomimetic effects. Tolcapone and COMT genotype (met/met) were associated with an increased report of feeling "mellow." CONCLUSIONS: The interaction between COMT rs4680 polymorphisms and tolcapone on the cognitive, but not on the psychotomimetic and overall subjective effects of THC, suggests that modulation of dopaminergic signaling may selectively influence specific cannabinoid effects in healthy individuals. The role of dopaminergic signaling in the cognitive effects of cannabinoids should be considered in drug development efforts targeting these effects. CLINICALTRIALS.GOV REGISTRATION: https://clinicaltrials.gov/ct2/show/NCT00678730?term=NCT00678730&rank=1 ClinicalTrials.gov Identifier: NCT00678730.
RATIONALE: The catechol-O-methyl transferase (COMT) enzyme has been implicated in determining dopaminergic tone and the effects of delta-9-tetrahydrocannabinol (THC) in the human brain. OBJECTIVE: This study was designed to evaluate the effect of (1) a functional polymorphism and (2) acute pharmacological inhibition of COMT on the acute response to THC in humans. METHODS: Sub-study I: The effect of intravenous (IV) THC (0.05 mg/kg) was investigated in 74 healthy subjects genotyped for the COMT rs4680 (Val/Met) polymorphism in a 2-test-day double-blind, randomized, placebo-controlled study. Sub-study II: COMT rs4680 homozygous subjects (Val/Val and Met/Met) from sub-study I received the COMT enzyme inhibitor tolcapone (200 mg) followed by IV THC or placebo on two additional test days. Subjective, behavioral, and cognitive data were obtained periodically on each test day. RESULTS: Sub-study I: Val/Val individuals were most sensitive to THC-induced attention and working memory deficits. In contrast, the psychotomimetic and subjective effects of THC were not influenced by COMT genotype. Sub-study II: Tolcapone reduced THC-induced working memory deficits, but not THC's psychotomimetic effects. Tolcapone and COMT genotype (met/met) were associated with an increased report of feeling "mellow." CONCLUSIONS: The interaction between COMT rs4680 polymorphisms and tolcapone on the cognitive, but not on the psychotomimetic and overall subjective effects of THC, suggests that modulation of dopaminergic signaling may selectively influence specific cannabinoid effects in healthy individuals. The role of dopaminergic signaling in the cognitive effects of cannabinoids should be considered in drug development efforts targeting these effects. CLINICALTRIALS.GOV REGISTRATION: https://clinicaltrials.gov/ct2/show/NCT00678730?term=NCT00678730&rank=1 ClinicalTrials.gov Identifier: NCT00678730.
Authors: Roberto Ceravolo; Paola Piccini; Dale L Bailey; Karin M Jorga; Helen Bryson; David J Brooks Journal: Synapse Date: 2002-03-01 Impact factor: 2.562
Authors: Aine T Behan; Magdalena Hryniewiecka; Colm M P O'Tuathaigh; Anthony Kinsella; Mary Cannon; Maria Karayiorgou; Joseph A Gogos; John L Waddington; David R Cotter Journal: Neuropsychopharmacology Date: 2012-03-21 Impact factor: 7.853
Authors: José A Apud; Venkata Mattay; Jingshan Chen; Bhaskar S Kolachana; Joseph H Callicott; Roberta Rasetti; Guilna Alce; Jennifer E Iudicello; Natkai Akbar; Michael F Egan; Terry E Goldberg; Daniel R Weinberger Journal: Neuropsychopharmacology Date: 2006-10-25 Impact factor: 7.853
Authors: Emma Barkus; Paul D Morrison; D Vuletic; John C Dickson; Peter J Ell; Lyn S Pilowsky; Rudolf Brenneisen; David W Holt; John Powell; Shitij Kapur; Robin M Murray Journal: J Psychopharmacol Date: 2010-09-17 Impact factor: 4.153
Authors: Matthijs G Bossong; Bart N M van Berckel; Ronald Boellaard; Lineke Zuurman; Robert C Schuit; Albert D Windhorst; Joop M A van Gerven; Nick F Ramsey; Adriaan A Lammertsma; René S Kahn Journal: Neuropsychopharmacology Date: 2008-08-27 Impact factor: 7.853
Authors: Avshalom Caspi; Terrie E Moffitt; Mary Cannon; Joseph McClay; Robin Murray; HonaLee Harrington; Alan Taylor; Louise Arseneault; Ben Williams; Antony Braithwaite; Richie Poulton; Ian W Craig Journal: Biol Psychiatry Date: 2005-05-15 Impact factor: 13.382
Authors: Matthijs G Bossong; Mitul A Mehta; Bart N M van Berckel; Oliver D Howes; René S Kahn; Paul R A Stokes Journal: Psychopharmacology (Berl) Date: 2015-03-25 Impact factor: 4.530
Authors: Michael A P Bloomfield; Celia J A Morgan; Alice Egerton; Shitij Kapur; H Valerie Curran; Oliver D Howes Journal: Biol Psychiatry Date: 2013-06-29 Impact factor: 13.382